Craig Hutchinson is a senior research project manager at Gilead Sciences within the Research Strategy Innovation and Portfolio group. In this role, he supports six clinical-stage drug products developed to treat viral diseases. The products are small molecules for weekly and monthly oral drugs for the treatment and prevention of HIV.

Mr. Hutchinson is a former community engagement director at the San Francisco AIDS Foundation, where he managed community programs to build awareness, health promotion, and social justice in diverse communities within the San Francisco area.

In 2012, Mr. Hutchinson joined Westside Mental Health Community Services as director of HIV prevention programs. In addition to his leadership role at Westside, he managed a NIMH-funded research project in collaboration with the Alameda County Public Health Department and the University of California, Los Angeles, Semel Institute for Neuroscience and Human Behavior. The study focused on heterosexual African American HIV-serodiscordant couples in Oakland, Calif. and Los Angeles that have a high prevalence of HIV and risk conditions among African Americans.

Mr. Hutchinson’s international work includes consulting with the Barbados Ministry of Health for a formative assessment. This assessment occurred before the National HIV Behavioral Surveillance Survey conducted by the U.S. Centers for Disease Control and Prevention to understand better the men who have sex with men (MSM) community in Barbados and provided operational information for a planned MSM behavioral study using respondent-driven sampling.

Mr. Hutchinson received a B.A. with honors from the University of California, Berkeley. While pursuing an M.P.H. at Columbia University, Mailman School of Public Health in New York, he was a research counselor with the New York Blood Center on the HPTN 061 (BROTHERS) study. This study determined the feasibility and acceptability of a multifaceted intervention among Black MSM.